XENON PHARMACEUTICALS INC
XENENASDAQ🏆 #1563 by market capEarnings Nov 2 · PostUS Equity
$37.25▲ $0.53 (+1.43%)
Market closed · at closeTrack XENE
Get earnings, price moves & breaking news on Telegram
24h▲ 1.4%
7d▲ 1.8%
14d▼ 34.4%
30d▼ 38.2%
ytd▼ 16.9%
1y▼ 7.2%
🏦Market Cap
$3.60B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
XENON PHARMACEUTICALS INC
XENEAnalyst Ratings
Price
$37.25
Total
22
Raised
0
Lowered
1
Avg PT
$68.63
H / L
$90 / $46
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Needham | Reiterated | Buy | 2026-09-18 | $60.00 | +61.10% |
Baird | Reiterated | Outperform | 2026-09-18 | — | — |
Deutsche Bank | Downgraded | Buy → Hold | 2026-09-18 | $46.00 | +23.50% |
Wells Fargo | Reiterated | Overweight | 2026-09-18 | $64.00 | +71.80% |
Wedbush | Reiterated | Outperform | 2026-09-18 | $55.00 | +47.70% |
RBC Capital | Reiterated | Outperform | 2026-09-18 | $70.00 | +87.90% |
JP Morgan | Reiterated | Overweight | 2026-05-27 | — | — |
HC Wainwright & Co. | Reiterated | Buy | 2026-03-10 | — | — |
Chardan Capital | Reiterated | Buy | 2025-10-07 | — | — |
Goldman Sachs | Reiterated | Buy | 2025-04-17 | $60.00 | +61.10% |
Cantor Fitzgerald | Reiterated | Overweight | 2024-08-09 | $55.00 | +47.70% |
Citigroup | Reiterated | Buy | 2024-05-10 | — | — |
B of A Securities | Reiterated | Buy | 2024-01-02 | — | — |
Stifel | Reiterated | Buy | 2023-12-18 | — | — |
Guggenheim | Reiterated | Buy | 2023-06-15 | $90.00 | +141.60% |
Cowen & Co. | Reiterated | Outperform | 2022-12-12 | — | — |
Raymond James | Reiterated | Outperform | 2022-10-19 | $50.00 | +34.20% |
SVB Leerink | Reiterated | Outperform | 2022-08-11 | — | — |
William Blair | Reiterated | Outperform | 2020-01-08 | — | — |
Stifel Nicolaus | Reiterated | Buy | 2018-08-08 | $89.00 | +139.00% |
Jefferies | Reiterated | Buy | 2016-03-09 | $90.00 | +141.60% |
Canaccord Genuity | Reiterated | Buy | 2015-07-02 | — | — |
Institution
Needham
Reiterated · Buy · 2026-09-18
$60.00
+61.10%
Baird
Reiterated · Outperform · 2026-09-18
—
—
Deutsche Bank
Downgraded · Buy → Hold · 2026-09-18
$46.00
+23.50%
Wells Fargo
Reiterated · Overweight · 2026-09-18
$64.00
+71.80%
Wedbush
Reiterated · Outperform · 2026-09-18
$55.00
+47.70%
RBC Capital
Reiterated · Outperform · 2026-09-18
$70.00
+87.90%
JP Morgan
Reiterated · Overweight · 2026-05-27
—
—
HC Wainwright & Co.
Reiterated · Buy · 2026-03-10
—
—
Chardan Capital
Reiterated · Buy · 2025-10-07
—
—
Goldman Sachs
Reiterated · Buy · 2025-04-17
$60.00
+61.10%
Cantor Fitzgerald
Reiterated · Overweight · 2024-08-09
$55.00
+47.70%
Citigroup
Reiterated · Buy · 2024-05-10
—
—
B of A Securities
Reiterated · Buy · 2024-01-02
—
—
Stifel
Reiterated · Buy · 2023-12-18
—
—
Guggenheim
Reiterated · Buy · 2023-06-15
$90.00
+141.60%
Cowen & Co.
Reiterated · Outperform · 2022-12-12
—
—
Raymond James
Reiterated · Outperform · 2022-10-19
$50.00
+34.20%
SVB Leerink
Reiterated · Outperform · 2022-08-11
—
—
William Blair
Reiterated · Outperform · 2020-01-08
—
—
Stifel Nicolaus
Reiterated · Buy · 2018-08-08
$89.00
+139.00%
Jefferies
Reiterated · Buy · 2016-03-09
$90.00
+141.60%
Canaccord Genuity
Reiterated · Buy · 2015-07-02
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space